Long-term survival of more than 3 years among patients with advanced non-small cell lung cancer treated with chemotherapy

• 作者: Akira Ono Asuka Tsuya Haruyasu Murakami Hirotsugu Kenmotsu Kyoichi Kaira Masahiro Endo Nobuyuki Yamamoto Rieko Kaira Takehito Shukuya Tateaki Naito Toshiaki Takahashi Yukiko Nakamura
• 来源期刊: 世界呼吸病学杂志
• 学科: 医学
• 关键词: NON-SMALL cell lung cancer Long-term SURVIVOR CHEMOTHERAPY Performance status EPIDERMAL growth factor receptor-tyrosine kinase inhibitors
• 年，卷（期）: 2013,（3）
• 页码范围: 110-115
• 页数: 6页
• 分类号: R

摘要

AIM:To evaluate the prognostic factors of long-term survival of more than 3 years in patients with advanced non-small cell lung cancer(NSCLC).METHODS:We retrospectively analyzed the records of 474 patients with advancedⅢB/ⅣNSCLC who received chemotherapy as initial treatment between September 2002 and March 2007.RESULTS:The median survival time(MST)was 12.5 mo and the 3 year and 5 year survival rates were 14.6%and 5.3%,respectively.Long-term survival of more than 3 and 5 years was observed in 65 and 16 patients,respectively.The MST for the 65 patients was 61.5 mo(range,60.1-81.0 mo).In the 474 patients,a good performance status(PS),female sex,non-smoking status and adenocarcinoma histology were significantly associated with a favorable outcome.Furthermore,female sex,a good PS,non-smoking status and adenocarcinoma histology were significantly correlated with longterm survival of more than 3 years and most of these patients(89.2%,58/65)received epidermal growth factor receptor-tyrosine kinase inhibitors as any line treatment.Survival analysis of long-term survivors showed that a PS of 0 was an independent prognostic factor for predicting favorable outcomes.CONCLUSION:Our results suggest that a good PS and adenocarcinoma histology play an important role in long-term survival of more than 3 years.A PS of 0 was an independent prognostic factor for predicting favorable outcomes in patients with advanced NSCLC who survived for more than 3 years.